Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SRC | P12931 | 18/20 | 0.80 |
| ▸ | PIK3CD | O00329 | 17/20 | 0.80 |
| ▸ | PIK3CA | P42336 | 17/20 | 0.80 |
| ▸ | PIK3CB | P42338 | 17/20 | 0.80 |
| ▸ | PIK3CG | P48736 | 17/20 | 0.80 |
| ▸ | PRKDC | P78527 | 17/20 | 0.80 |
| ▸ | ABL1 | P00519 | 17/20 | 0.80 |
| ▸ | EGFR | P00533 | 16/20 | 0.80 |
| ▸ | HCK | P08631 | 16/20 | 0.80 |
| ▸ | MTOR | P42345 | 16/20 | 0.80 |
| ▸ | EPHB4 | P54760 | 16/20 | 0.80 |
| ▸ | PI4KB | Q9UBF8 | 11/20 | 0.80 |
| ▸ | KDR | P35968 | 15/20 | 0.72 |
| ▸ | NUDT14 | O95848 | 1/20 | 0.59 |
| ▸ | NUDT5 | Q9UKK9 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23917199 | 0.92 | PIK3CD (0.75) | SRCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL130481 | 0.89 | PIK3CD (0.71) | SRCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL129883 | 0.89 | PIK3CD (0.74) | SRCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL23917517 | 0.89 | PIK3CD (0.83) | SRCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL130598 | 0.89 | SRC (0.75) | SRCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL23917270 | 0.89 | PIK3CD (1.00) | SRCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL218160 | 0.89 | SRC (0.75) | SRCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL23917203 | 0.87 | SRC (0.72) | SRCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL2469676 | 0.84 | SRC (1.00) | SRCPIK3CDPIK3CAPIK3CBPIK3CG | |
| SCHEMBL6055041 | 0.84 | SRC (1.00) | SRCPIK3CDPIK3CAPIK3CBPIK3CG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11858907-B2 | Kinase modulators | RHIZEN PHARMACEUTICALS AG (CH) | 2024-01-02 | — | — | US | disclosed |
| US-20210401840-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2021-12-30 | — | — | US | disclosed |
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | MEDIVATION TECHNOLOGIES, INC. (US) | 2021-10-14 | — | — | US | disclosed |
| US-11020399-B2 | Intermediates useful in the synthesis of compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2021-06-01 | — | — | US | disclosed |
| US-20200239427-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2020-07-30 | — | — | US | disclosed |
| US-10442783-B2 | 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2019-10-15 | — | — | US | disclosed |
| US-20190282581-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2019-09-19 | — | — | US | disclosed |
| US-10322130-B2 | Substituted chromenones as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2019-06-18 | — | — | US | disclosed |
| US-20190105324-A9 | SUBSTITUTED CHROMENONES AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2019-04-11 | — | — | US | disclosed |
| US-10220035-B2 | Compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2019-03-05 | — | — | US | disclosed |
| US-20150320752-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS AG (CH) | 2015-11-12 | — | — | US | disclosed |
| US-20150174131-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS AG (CH) | 2015-06-25 | — | — | US | disclosed |
| US-9018375-B2 | Substituted chromenes as kinase modulators | RHIZEN PHARMACEUTICALS SA (CH) | 2015-04-28 | — | — | US | disclosed |
| US-20140080827-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2014-03-20 | — | — | US | disclosed |
| US-8642607-B2 | 4H-chromen-4-one compounds as modulators of protein kinases | RHIZEN PHARMACEUTICALS SA (CH) | 2014-02-04 | — | — | US | disclosed |
| WO-2012151525-A9 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2012-12-13 | — | — | WO | disclosed |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2012-11-15 | — | — | US | disclosed |
| WO-2012151525-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | RHIZEN PHARMACEUTICALS SA (CH) | 2012-11-08 | — | — | WO | disclosed |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | INCOZEN THERAPEUTICS PVT. LTD. (IN) | 2012-03-08 | — | — | US | disclosed |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | RHIZEN PHARMACEUTICALS SA (CH) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (16 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10442783-B2 | 2,3-disubstituted chromen-4-one compounds as modulators of protein kinases | PIK3CB, PIK3CD, PDPK1 | SRC 202/4885PIK3CD 2/4885PIK3CA 4/4885 |
| US-20210401840-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | SRC 285/4885PIK3CD 47/4885PIK3CA 88/4885 |
| US-20150174131-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | SRC 314/4885PIK3CD 70/4885PIK3CA 143/4885 |
| US-11020399-B2 | Intermediates useful in the synthesis of compounds as modulators of protein kinases | MAP4K2, MAP3K20, MAP3K1 | SRC 85/4885PIK3CD 288/4885PIK3CA 221/4885 |
| US-20150320752-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | SRC 285/4885PIK3CD 47/4885PIK3CA 88/4885 |
| US-20120289496-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | SRC 285/4885PIK3CD 47/4885PIK3CA 88/4885 |
| US-20190105324-A9 | SUBSTITUTED CHROMENONES AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKAR2B | SRC 254/4885PIK3CD 89/4885PIK3CA 106/4885 |
| US-10220035-B2 | Compounds as modulators of protein kinases | PRKCA, PRKCH, PRKCE | SRC 205/4885PIK3CD 30/4885PIK3CA 64/4885 |
| US-20140080827-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | SRC 314/4885PIK3CD 70/4885PIK3CA 143/4885 |
| US-20190282581-A1 | NOVEL COMPOUNDS AS MODULATORS OF PROTEIN KINASES | PRKCA, PRKCH, PRKCB | SRC 285/4885PIK3CD 47/4885PIK3CA 88/4885 |
| US-20110118257-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | SRC 314/4885PIK3CD 70/4885PIK3CA 143/4885 |
| US-20210317140-A1 | Heterocyclic Compounds and Methods of Use | BTK, PIK3CD, PIK3CB | SRC 92/4885PIK3CD 2/4885PIK3CA 6/4885 |
| US-20200239427-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | SRC 314/4885PIK3CD 70/4885PIK3CA 143/4885 |
| US-10322130-B2 | Substituted chromenones as modulators of protein kinases | MAP3K1, CSNK1A1, MAP3K2 | SRC 90/4885PIK3CD 148/4885PIK3CA 153/4885 |
| US-11858907-B2 | Kinase modulators | RPS6KA1, RPS6KA2, PRKAR2A | SRC 110/4885PIK3CD 103/4885PIK3CA 144/4885 |
| US-20120059001-A1 | NOVEL KINASE MODULATORS | PRKCA, PRKCH, PRKCB | SRC 314/4885PIK3CD 70/4885PIK3CA 143/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.